SpotitEarly Overview
SpotitEarly develops scent based multi-cancer early detection screening test, combining proprietary AI stack with bio-detectors, to detect cancer at its early stages and save people’s lives. Spotitearly is currently conducting a large clinical trial for screening breast, lung, colon and prostate cancers in one test. During training phase, the test showed higher sensitivity and better specificity in detecting early stages of cancer compared to any existing test on the market today.
Cumulative Funding Raised Over Time ($)
Latest News
growth-positive
AI biotech firm SpotitEarly raises $20.3M to scale noninvasive cancer detection in US - SiliconANGLE
SpotitEarly Ltd., an Israeli AI biotech startup, has raised $20.3 million to expand its presence in the U.S. and enhance its cancer detection technology. The company, founded in 2020, is developing a noninvasive breath test for early cancer detection using AI and canines to analyze volatile organic compounds in exhaled breath. Their LUCID platform, which integrates hardware and software, has shown 94% accuracy in a clinical trial. The funding will help make home testing kits available in the U.S. by 2026. Notable investors include Hanaco Venture Capital, Menomedin Venture Capital, Jeff Swartz, and Avishai Abrahami.
InvestmentProduct StageExpand
growth-positive
מאבחנים על ארבע: החידוש הישראלי בגילוי מוקדם של סרטן
SpotitEarly, an Israeli startup, is conducting an innovative clinical trial at Assuta Ramat Hachayal Hospital to detect early-stage cancer using advanced AI technology and trained dogs sense of smell. The technology, which is patented in the US, can currently identify four types of cancer: lung, breast, prostate, and colon. Over $8 million has been invested in the company, with significant contributions from Israeli funds קרן מנומדין and קרן הנקו. The trial has tested over 1,400 participants with a 94% accuracy rate. SpotitEarlys collaboration with Assuta and its innovation arm, Rise, aims to revolutionize early cancer detection, potentially saving millions of lives worldwide.
Product StagePartnersInvestment
growth-positive
Dogs' 93 Percent Success Rate At Sniffing Out Cancer
SpotitEarly, an Israeli company, has achieved a 92.8% success rate in using trained dogs to sniff out early signs of cancer. The dogs were able to identify cases of breast, lung, colon, and prostate cancer. SpotitEarly combines the dogs sense of smell with AI technology to assess patients breath samples. The company aims to revolutionize cancer screening tests and reduce the cost of the test to 25% of competing products. The clinical study involved 575 participants, including cancer patients and a control group. SpotitEarly plans to include a total of 2,000 participants in the study.
CustomersInvestment
growth-positive
SpotitEarly raises $6.2 million for early detection of cancers based on olfactory abilities of dogs CTech
Israeli biotech startup SpotitEarly has raised $6.2 million in a seed funding round led by Hanaco Ventures. The company is developing a technique for early detection of cancer that combines AI and algorithmics with the olfactory abilities of dogs. The test can detect lung, prostate, breast, and colon cancer, with more types to follow. The company is currently conducting one of the worlds most extensive clinical studies in this field, in partnership with the Sourasky Medical Center in Tel Aviv and the Hadassah Medical Center in Jerusalem.
Investment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $26.5M |
| Last funding | $20.3M |
| Stage | A |
| Rounds | 3 |
| Investors | 5 |
Team Members
4
Employees: 11-50
Web & Social Links
| Website | www.spotitearly.com |
Locations
Tel Aviv, Israel
Jerusalem, Israel
Photos & Videos
No files yet
